Equities Analysts Offer Predictions for Edwards Lifesciences Corp’s Q2 2019 Earnings (EW)

Equities Analysts Offer Predictions for Edwards Lifesciences Corp’s Q2 2019 Earnings (EW)

Edwards Lifesciences Corp (NYSE:EW) – Analysts at Svb Leerink issued their Q2 2019 earnings estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, April 24th, according to Zacks Investment Research. Svb Leerink analyst D. Antalffy forecasts that the medical research company will post earnings of $1.32 per share for the quarter. Svb Leerink also issued estimates for Edwards Lifesciences’ Q3 2019 earnings at $1.26 EPS, Q4 2019 earnings at $1.34 EPS, FY2019 earnings at $5.25 EPS, Q1 2020 earnings at $1.42 EPS, Q2 2020 earnings at $1.45 EPS, Q3 2020 earnings at $1.36 EPS, Q4 2020 earnings at $1.51 EPS, FY2020 earnings at $5.75 EPS and FY2021 earnings at $6.30 EPS.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group increased their price objective on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Monday, February 4th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Bank of America increased their price objective on shares of Edwards Lifesciences from $190.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Finally, Canaccord Genuity reissued a “buy” rating and set a $215.00 price objective (up previously from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $187.00.

Shares of EW traded up $0.66 during trading hours on Monday, hitting $172.66. The stock had a trading volume of 1,030,195 shares, compared to its average volume of 1,282,922. Edwards Lifesciences has a 52 week low of $134.38 and a 52 week high of $197.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.69 and a current ratio of 3.66. The firm has a market cap of $35.84 billion, a price-to-earnings ratio of 36.74, a PEG ratio of 2.22 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business had revenue of $993.00 million for the quarter, compared to analyst estimates of $989.87 million. During the same quarter in the prior year, the firm earned $1.22 EPS. The firm’s quarterly revenue was up 11.0% compared to the same quarter last year.

Several large investors have recently made changes to their positions in the stock. Executive Wealth Management LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $25,000. FTB Advisors Inc. bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $25,000. Sontag Advisory LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Lindbrook Capital LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $27,000. Finally, Capital Financial Planning LLC bought a new stake in Edwards Lifesciences during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 84.43% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,369 shares of the stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $175.06, for a total value of $939,897.14. Following the sale, the vice president now directly owns 26,043 shares in the company, valued at approximately $4,559,087.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Larry L. Wood sold 6,716 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $192.34, for a total transaction of $1,291,755.44. Following the completion of the sale, the vice president now owns 122,495 shares in the company, valued at $23,560,688.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 153,780 shares of company stock worth $27,129,483. Corporate insiders own 1.63% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Share:
Scroll Up
error: Content is protected !!